Guangzhou Pluslife Technology Co., Ltd.
Guangzhou, Guangdong Sheng, China
Purpose
To develop a next-generation molecular Point of Care Test (POCT) for detecting Rifampicin-resistant (RIF-resistant) TB to enable rapid diagnosis of drug-resistant TB, particularly in low-resource settings with high disease burden
Division
Global Health
Date
November 2024
Region Served
AFRICA, ASIA
Committed amount
$3,942,400
Grant topic
Enterics, Diagnostics, Genomics & Epidemiology, Tuberculosis
Duration (months)
50
Grantee location
Guangzhou, Guangdong Sheng, China
More about our financials
Our story
Learn about the origins of the foundation and the values that drive our work.
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.